My watch list  

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and development via subsidiaries based in Melbourne, Australia and New York and specialises in discovering new molecules with an improved therapeutic profile for the treatment of cancer. Cytopia’s lead compound, CYT997, is currently in Phase II clinical trials.

More about Cytopia
  • News

    YM BioSciences completes merger with Cytopia

    YM BioSciences Inc. announced that the merger of Cytopia Limited into YM under a Scheme of Arrangement, has been concluded. "With the completion of this transaction, our pipeline has been expanded to incorporate Cytopia's two lead clinical candidates, CYT387 and CYT997 and its impressive p ... more

    YM BioSciences announces offer for Cytopia Ltd.

    YM BioSciences Inc. announced it has proposed to merge Cytopia Ltd., a clinical-stage, Melbourne-based drug development company, into YM. Cytopia's lead products are CYT997, a novel vascular disrupting agent (VDA) currently in Phase II trials, and CYT387, a novel, orally-active JAK2 inhibi ... more

    Cytopia cancer program reaches important milestone at Cancer Therapeutics CRC

    Cytopia Limited announced significant progress by Cancer Therapeutics CRC Pty Ltd (CTx) towards the identification of a pre-clinical drug candidate. This candidate is based on intellectual property licensed from Cytopia to CTx. In May 2008, Cytopia and CTx entered into an agreement where ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE